Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 180Cisplatin 44Paclitaxel 41Carboplatin 41lenvatinib 31Docetaxel 22Pemetrexed 20Fluorouracil 19Capecitabine 16Gemcitabine 15Saline Solution 13Oxaliplatin 13Albumin-Bound Paclitaxel 10epacadostat 9130-nm albumin-bound paclitaxel 9Leucovorin 8Cetuximab 8olaparib 7Irinotecan 7Bevacizumab 7Etoposide 6belzutifan 5Dexamethasone 5enzalutamide 4trifluridine tipiracil drug combination 3regorafenib 3patritumab deruxtecan 3enfortumab vedotin 3durvalumab 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Parkinson Disease 4, Autosomal Dominant Lewy Body × Histamine Antagonists × Clear all
NCT06788912 2026-06-01

MK-3475-01E

Merck Sharp & Dohme LLC

Phase 2 Recruiting
60 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT05319730 2026-05-26

MK-3475-06B

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
230 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡